Early detection saves lives
October is Breast Cancer Awareness month. It is an important cause to raise awareness and understanding about breast cancer and detect early signs.
Breast cancer is the most common cancer in Finland and one in every eight Finnish woman suffers from breast cancer at some point in her life. Fortunately, breast cancer screening programs have led to earlier diagnosis. The prognosis has improved significantly as cancers are diagnosed earlier and treatment methods have evolved.
However, metastatic breast cancer has no cure. Estimated 20-30% patients diagnosed with cancer will develop metastatic breast cancer but less than 7% of breast cancer research funding is allotted to metastatic breast cancer research.
Bone is the most common site of breast cancer metastasis. Bone metastasis can occur anywhere in human body, but the commonly affected bones involve pelvis, spine, ribs and upper bones of arms and legs. Secondary cancer in bone can cause broken bones and fractures. Therefore, it is crucial to develop new treatments to improve life quality and life expectancy of patients with bone metastatic breast cancer.
Pharmatest has long experience with bone metastasis studies, and we have had a privilege of being involved in our customers’ success stories that can help the patients and their families. Read more from our scientific review “The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis”.
Supporting breast cancer research is an important cause for many of Pharmatest’s Team members. It has personally affected many of us and created even stronger passion, devotion, and drive towards our research.
Join the cause and contact your local cancer foundation to get involved to make a difference to prevent and cure the disease.
Finnish Cancer Foundation and Pink Ribbon donations https://roosanauha.syopasaatio.fi/